[et_pb_section fullwidth=”off” specialty=”off” background_image=”http://www.curecancertoday.com/wp-content/uploads/2016/03/cllslide.jpg” transparent_background=”off” background_color=”#ffffff” allow_player_pause=”off” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row][et_pb_column type=”4_4″][et_pb_image admin_label=”Image” show_in_lightbox=”off” url_new_window=”off” animation=”off” sticky=”off” src=”http://www.curecancertoday.com/wp-content/uploads/2016/03/facts.png” /][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section][et_pb_row][et_pb_column type=”4_4″][et_pb_tabs admin_label=”Facts”][et_pb_tab title=”About Leukemia”]

normalvleukemiaLeukemia is a cancer of marrow and blood.  There are four main subtypes of leukemia: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML).


In 2015, 54,270 people are expected to be diagnosed with leukemia.


There are an estimated 327,520 people living with, or in remission from, leukemia in the US.


  • The overall five-year relative survival rate for leukemia has more than quadrupled since 1960. From 1960 to 1963, the five-year relative survival rate among whites (only data available) with leukemia was 14 percent. From 1975 to 1977, the five-year relative survival rate for the total population with leukemia was 34.2 percent, and from 2004 to 2010, the overall relative survival rate was 60.3 percent.
  • From 2004-2010, the five-year relative survival rates overall were
    • CML – 59.9 percent
    • CLL – 83.5 percent
    • AML – 25.4 percent overall and 66.3 percent for children and adolescents younger than 15 years
    • ALL – 70 percent overall, 91.8 percent for children and adolescents younger than 15 years, and 93 percent for children younger than 5 years.


  • In 2015, 24,450 people are expected to die from leukemia (14,040 males and 10,050 females).
  • In 2007-2011, leukemia was the fifth most common cause of cancer deaths in men and the sixth most common in women in the US.


  • Facts 2014-2015. The incidence, prevalence and mortality data in Facts 2014-2015 reflect the statistics from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program, Cancer Statistics Review (CSR) 1975-2011.
  • Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015.

[/et_pb_tab][et_pb_tab title=”About MWOY”]


The Leukemia & Lymphoma Society’s (LLS) Man & Woman of the Year campaign is a fundraising competition among a select group of individuals in the community. While each candidate conducts their own campaign, all candidates are united by one goal: to use their leadership skills to raise funds to help blood cancer patients live longer and healthier lives.


By accepting the nomination, candidates will have 10 weeks beginning the day of the kickoff to accumulate the most “votes.” Every dollar raised counts as one vote. The male and female candidates who raise the most votes during the campaign are named the Delaware Chapter’s Man & Woman of the Year at the Grand Finale Celebration on June 11, 2016.


Candidates run in honor of the Boy & Girl of the Year, who are local blood cancer survivors and sources of inspiration. Candidates are people who are passionate about finding cures for leukemia, lymphoma and myeloma. The diverse class candidates and nominees, who may or may not have a personal connection to blood cancer, always have two qualities in common: passion and philanthropy.


More than 1 million people in the United States are living with, or are in remission from a blood cancer. Someone new is diagnosed with a blood cancer every four minutes. New cases of leukemia, lymphoma and myeloma will account for nine percent of the 1.5 million new cancer diagnoses in the United States this year.
We rely on the generosity of individuals, corporations and foundations. Proceeds from the 2016 Man & Woman of the Year support our mission to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.


[/et_pb_tab][et_pb_tab title=”Where Does the Money Go?”]


[/et_pb_tab][et_pb_tab title=”About LLS”]


The Leukemia & Lymphoma Society® (LLS) exists to find cures and ensure access to treatments for all blood cancer patients. LLS is the world’s largest voluntary health agency dedicated to blood cancers. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.


  • Investing in blood cancer research: LLS has invested more than $1 billion in blood cancer research, approximately $67.2 million in fiscal year 2015 alone. Research funded by LLS has played a role in advances such as the discovery and development of chemotherapy, bone marrow and stem cell transplantation, and new, targeted oral therapies and immunotherapies.
  • From 2000 through 2014, almost 40 percent of new anti-cancer drugs were FDA approved for blood cancer patients — more first-ever approvals than for any other group of cancers — and many of these were advanced with funding from LLS. Some therapies are even helping patients with other cancers and other serious, nonmalignant diseases.
  • Providing critical information and support for patients and their families: We are the leading source of free blood cancer information, education and support for patients, survivors, families and healthcare professionals. To date, our co-pay assistance program has provided $237 million to help eligible blood cancer patients afford health-insurance premiums and prescription drug co-pays. The program has assisted nearly 55,000 patients since its inception in 2007.
  • Advocating for issues impacting blood cancer patients: LLS advocacy pushed legislation in 14 states to provide equitable insurance coverage of orally-administered cancer treatments while also pushing federal legislation that can accelerate FDA drug approvals and address drug shortage issues.


The need is critical: Nearly 1.2 million people in North America are living with, or are in remission from, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma and myelodysplastic syndromes. Approximately every three minutes, someone new is diagnosed with blood cancer. Approximately every 10 minutes, someone with a blood cancer dies. Thanks to research, survival rates for patients with many blood cancers have doubled, tripled and even quadrupled since the early 1960s. Despite these advances, about one third of patients with a blood cancer still do not survive even five years after their diagnosis, which is why more funding is needed to bring better therapies to patients, and faster.


As a nonprofit, we rely on the generosity of individuals, corporations and foundations. Major, annual fundraising campaigns include Team In Training, Light The Night Walk, Student Series, Man & Woman of the Year and The Leukemia Cup Regatta.


In addition to our national headquarters in White Plains, NY, we have a network of local chapters across the United States and Canada. Information on blood cancers and support is available through our IRC and at www.LLS.org.

[/et_pb_tab][/et_pb_tabs][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fullwidth=”off” specialty=”off”][et_pb_row][et_pb_column type=”4_4″][et_pb_image admin_label=”Image” src=”http://www.curecancertoday.com/wp-content/uploads/2016/02/dot.jpg” show_in_lightbox=”off” url_new_window=”off” animation=”off” sticky=”off” /][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section][et_pb_row][/et_pb_row][/et_pb_section]